Decreasing Rx co-payments boost drug adherence by chronic disease patients
Chronic disease patients are more compliant when Rx co-payments decrease.
Removing economic barriers to treatment for chronic conditions encourages patients to remain on recommended therapies, according to a new study published in the January/February 2008 issue of Health Affairs. The study, funded in part by GlaxoSmithKline, investigated the impact on medication adherence of reducing prescription co-paymentsin addition to existing disease management programsfor employees of a leading service industry company. "The Impact of Decreasing Co-payments on Medication Adherence in the Context of a Disease Management Program" covered a 12-month study. Co-payment rates for generic medications were reduced from $5 to $0; co-payments for branded drugs were cut in half.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
